Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Follow-Up Questions
What is the price performance of TLPPF stock?
The current price of TLPPF is $10.25, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Telix Pharmaceuticals Ltd?
Telix Pharmaceuticals Ltd belongs to Biotechnology industry and the sector is Health Care
What is Telix Pharmaceuticals Ltd market cap?
Telix Pharmaceuticals Ltd's current market cap is $3.4B
Is Telix Pharmaceuticals Ltd a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Telix Pharmaceuticals Ltd, including 5 strong buy, 9 buy, 2 hold, 0 sell, and 5 strong sell
